Class / Patent application number | Description | Number of patent applications / Date published |
514470000 | Chalcogen or nitrogen bonded directly to the hetero ring | 70 |
20080227856 | Materials and Methods for Creating Customized Compositions Having a Temporary Visual Indicator - The present invention relates to novel compositions, which provide an indicator for location and/or concentration of the composition during application. Following application, the indicator is no longer visible to the user. In one embodiment, the indicator is a compound that is visible at a first pH and not visible at a second pH. In another embodiment, the indicator is a photosensitive or light unstable dye, where the dye is visible for a temporary period following exposure to light. | 09-18-2008 |
20080269322 | Substituted Aminophenylsulfonamide Compounds as Hiv Protease Inhibitor - The present invention concerns substituted aminophenylsulfonamide compounds, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents. | 10-30-2008 |
20080280977 | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid - Provided are processes for the preparation of mycophenolate mofetil and other esters of mycophenolic acid. | 11-13-2008 |
20080293807 | Skin Cosmetic and Wrinkle-Reducing Agent - It is intended to provide a skin cosmetic and a wrinkle-reducing agent which are excellent in improving wrinkles caused by photoaging. Namely, a skin cosmetic and a wrinkle-reducing agent containing isosorbide which is represented by the following structural formula (1). | 11-27-2008 |
20080319056 | Butylphthalide Self-Emulsifying Drug Delivery System, Its Preparation Method and Application - The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug. | 12-25-2008 |
20090023805 | METHOD OF ADMINISTRATION - The present invention relates to the use of mycophenolic acid, a salt or prodrug thereof in immunosuppression, particularly for prevention or treatment of transplant rejection and immune-mediated and/or inflammatory diseases, wherein mycophenolic acid, the salt or the prodrug thereof is administered with an initial intensified dosage regimen. | 01-22-2009 |
20090088469 | METHOD FOR THE PREPARATION OF CITALOPRAM - Method for the preparation of citalopram comprising reaction of a compound of Formula (IV) wherein R is halogen, or CF | 04-02-2009 |
20090176873 | NOVEL USE OF ORGANIC COMPOUNDS - The present invention relates to the use of compounds of the formula (I) | 07-09-2009 |
20090192218 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS - The present invention relates to the use of a compound as effective agent for the prevention or treatment of diabetes mellitus in a mammal. Said compounds being selected from the group of phthalide derivatives and exhibit excellent blood glucose lowering effects and thus are effective agents in the prevention or treatment of diabetes mellitus in mammals. | 07-30-2009 |
20090209639 | PROCESS FOR MODIFYING DRUG CRYSTAL FORMATION - A process for modifying the crystal habit of acicular drug substances, crystals obtained by such a process, and particular crystal forms or modifications of mycophenolic acid or mycophenolate sodium are provided, as well as pharmaceutical compositions comprising the crystals, methods of treatment and uses thereof. | 08-20-2009 |
20090281177 | Butylphthalide Intravenous Emulsion and Application Thereof - The present invention discloses a butylphthalide intravenous emulsion for intravenous injection or infusion, containing butylphthalide or derivatives thereof as an active ingredient in an amount of 0.01˜50 wt % and an excipient in an amount of 50˜99.99 wt %, based on the total weight of the emulsion. | 11-12-2009 |
20090306201 | SELECTIVE INHIBITORS FOR TRANSFERASES - A pharmaceutical composition comprising a compound of formula I or II and a pharmaceutically acceptable carrier. Methods for treating a proliferative disorder mediated by a methyl transferase comprising administering an anti-proliferative effective amount of the compound of formula I or II are also presented. | 12-10-2009 |
20100010082 | FORMULATIONS FOR TREATING EYE DISORDERS - The present disclosure relates to ophthalmic solutions and methods of using the solutions to treat ocular disorders | 01-14-2010 |
20100022638 | ISOSORBIDE NITRATES - The present invention relates to new 3-substituted 6-nitrooxy-hexahydrofuro[3,2-b]furane derivatives possessing a superior pharmacological activity in thrombosis and in coronary ischemia models. | 01-28-2010 |
20100113589 | Deuterated darunavir - This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a human immunodeficiency virus (HIV) protease inhibitor, such as darunavir. | 05-06-2010 |
20100144864 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS - Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination with one or more lipid altering agents and/or PDE inhibitors. | 06-10-2010 |
20100144865 | COMPOUND FEED FOR AQUACULTURE - The present invention relates to a fish feed comprising dioxabicyclo[3.3.0]octane derivates, in particular selected sesame lignans, and a vegetable oil or oil mixture comprising at least one 18-carbon chain omega-3 fatty acid. The dioxabicyclo[3.3.0]octane derivate will induce a desaturation and elongation of the 18-carbon chain fatty acid in the fish muscle into longer carbon chain polyunsaturated fatty acids. | 06-10-2010 |
20100184852 | ORGANIC COMPOUNDS FOR TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION - The present invention refers to compounds of the general formula (I) wherein R | 07-22-2010 |
20100204316 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR - New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed. | 08-12-2010 |
20100210717 | PHARMACEUTICAL COMPOSITIONS COMPRISING MYCOPHENOLIC ACID OR MYCOPHENOLATE SALT - The invention provides a solid dosage form, e.g. a tablet, comprising mycophenolic acid or mycophenolate salt and a process for its production. | 08-19-2010 |
20100267823 | AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS - The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with a phosphodiesterase (PDE) dependent disease or condition of the central nervous system, as well as methods, uses and other inventions related thereto. | 10-21-2010 |
20100286260 | MILNACIPRAN FORMULATIONS - The present invention provides formulations comprising milnacipran or pharmaceutically acceptable salts thereof (e.g., milnacipran hydrochloride), including immediate release formulations and modified formulations, such as delayed release and extended release formulations. The present invention provides formulations with improved stability and high bioavailability. Processes for preparing the formulations as well as methods of treating conditions by administering the formulations are also described. | 11-11-2010 |
20100298427 | Anti-inflammatory compositions and their use - The present invention relates to the use of compounds of the formula (I) | 11-25-2010 |
20110028543 | Formulations and methods of using nitric oxide mimetics in cancer treatment - The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals. | 02-03-2011 |
20110082201 | Use of L-Butylphthalide in the Manufacture of Medicaments for Prevention and Treatment of Cerebral Infarct - The present invention discloses the use of L-butylphthalide of formula (I) in the manufacture of medicaments for the prevention and treatment of cerebral infarct, especially induced by focal cerebral ischemia. | 04-07-2011 |
20110213028 | FATTY ACID MYCOPHENOLATE DERIVATIVES AND THEIR USES - The invention relates to fatty acid mycophenolate derivatives; compositions comprising an effective amount of a fatty acid mycophenolate derivative; and methods for treating and preventing organ rejection and autoimmune diseases such as systemic lupus erythematosus, psoriasis and multiple sclerosis comprising the administration of an effective amount of a fatty acid mycophenolate derivative. | 09-01-2011 |
20110288167 | Butylphthalide Intravenous Emulsion and Application Thereof - The present invention discloses a butylphthalide intravenous emulsion for intravenous injection or infusion, containing butylphthalide or derivatives thereof as an active ingredient in an amount of 0.01˜50 wt % and an excipient in an amount of 50˜99.99 wt %, based on the total weight of the emulsion. | 11-24-2011 |
20110313035 | POLYMORPHS OF DARUNAVIR - The present invention provides novel solvated forms of darunavir and processes for there preparation. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it. Thus, for example, darunavir 2-methyl-2-butanol solvate was dissolved in methylene dichloride, distilled under vacuum at 45° C. to obtain a residue, cyclohexane was added to the residue and stirred for 30 hours at 20 to 25° C., and the separated solid was filtered, washed with cyclohexane and dried under vacuum at 50° C. for 12 hours to yield darunavir amorphous form. | 12-22-2011 |
20120208875 | METHOD FOR INHIBITING BLOOD VESSEL STENOSIS - Provided is a method for inhibiting blood vessel stenosis in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from a group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound, and combinations thereof. Also provided is a method for inhibiting blood vessel stenosis in a subject, comprising administration to the subject an effective amount of an | 08-16-2012 |
20120245225 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF - The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory learning injury caused by neuronal cell injury using transformed animal model with beta-amyloid precursor gene, therefore the compounds can be useful in treating or preventing cognitive function disorder. | 09-27-2012 |
20120259006 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF - The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory learning injury caused by neuronal cell injury using transformed animal model with beta-amyloid precursor gene, therefore the compounds can be useful in treating or preventing cognitive function disorder. | 10-11-2012 |
20120283324 | ANTAGONISTS AND AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF - The present invention relates to antagonists and agonists of the human bitter-taste receptors hTAS2R40, hTAS2R43, hTAS2R44, hTAS2R46, and hTAS2R47. The invention also relates to methods for identifying further molecules that suppress or enhance bitter taste transduction or bitter taste response mediated by hTAS2R40, hTAS2R43, hTAS2R44, hTAS2R46, and/or hTAS2R47 and uses thereof. | 11-08-2012 |
20130072552 | CRYSTALLINE HYDROCHLORIDE SALT OF DARUNAVIR - The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it. | 03-21-2013 |
20130079398 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISORDERS COMPRISING SULFURETIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition for preventing or treating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof, and a method of using the composition to prevent or treat nervous system disorders. Moreover, the present invention relates to a functional food composition for alleviating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof. The pharmaceutical composition and the functional food composition can be effectively used to prevent or treat degenerative brain disorders caused by a variety of cerebral nervous system abnormalities in persons, as well as depressive disorder and anxiety. | 03-28-2013 |
20130123354 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS - Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination with one or more lipid altering agents and/or PDE inhibitors. | 05-16-2013 |
20130131161 | METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASES AND CONDITIONS - Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy. | 05-23-2013 |
20130158107 | NOVEL FLAVONOIDS AND USES THEREOF - The present invention provides novel flavonoids extracted from an alcohol extract of dehulled adlay seeds. The present invention also provides a process for the preparation of the flavonoid and a method for treating inflammation in a subject, which method comprises administering to said subject an effective amount of the flavonoid and a pharmaceutically acceptable carrier or excipient. | 06-20-2013 |
20130158108 | USES OF N-BUTYLIDENEPHTHALIDE IN TREATING A LIVER INJURY AND IMPROVING LIVER FUNCTION - Provided is a method for treating a liver injury such as fibrosis, cirrhosis and hepatitis as well as a method for restoring liver function in a subject, which includes administrating to the subject a therapeutically effective amount of n-butylidenephthalide having the formula (I) as an active ingredient, or a pharmaceutically acceptable salt of ester thereof: | 06-20-2013 |
20130197077 | Bicyclic Furanones with Low Toxicity for Microbial Control - A class of bicyclic brominated furanone structures that have reduced toxicity and high activity for inhibiting biofilm formation and quorum sensing by microbes. The molecules have two fused cyclic alkyl groups that provide a structural framework that retain one or more bromine groups on the structure. The bicyclic furanones have reduced toxicity to mammalian cells as compared to other brominated furanones but retain the ability to inhibit biofilm formation in bacterial populations. | 08-01-2013 |
20130225674 | USE OF DIBENZOFURANONE DERIVATIVES TO INHIBIT KINASES - The invention relates to a pharmaceutical product comprising a dibenzofuranone derivative as the active ingredient. The invention further relates to the use of dibenzofuranone derivatives to inhibit kinases, in particular serine/threonine kinases, to the use of dibenzofuranone derivatives for producing drugs and/or medicinal products for treatment, and to the use of dibenzofuranone derivatives as a diagnostic product for analyzing the role of protein kinases, in particular serine/threonine kinases, in particular protein kinase CK2 in cellular processes, the pathogenesis of diseases, ontogenesis and/or other developmental biological phenomena or relationships. | 08-29-2013 |
20130310452 | ANTIFUNGAL FLAVOURING INGREDIENTS AND COMPOSITIONS - The present invention relates to the use of flavouring ingredients and compositions as antifungal agents. The invention also relates to a method for preserving food products and beverages comprising adding said flavouring ingredients or compositions to the food product or beverage. | 11-21-2013 |
20140057977 | Induction of Arteriogenesis - The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition. | 02-27-2014 |
20140057978 | NOVEL USE OF BENZOFURANYLSULFONATES - Provided herein are compounds for use in the treatment of central nervous system (CNS)-trauma related disorders like spinal cord injuries. Pharmaceutical compositions, single unit dosage forms, and kit suitable for use for the treatment of (CNS)-trauma related disorders are also disclosed. | 02-27-2014 |
20140094514 | PHARMACEUTICAL AND FOOD COMPOSITIONS FOR PREVENTING OR TREATING DIABETES OR OBESITY - The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the | 04-03-2014 |
20140142174 | DARUNAVIR FORMULATIONS - This invention relates to solid oral dosage forms of the HIV inhibitor darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof. | 05-22-2014 |
20140171499 | Pseudopolymorphic Forms Of A HIV Protease Inhibitor - New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed. | 06-19-2014 |
20140221474 | Method and Formulation for Chemical Peeling - A chemical peeling formulation and a formulation able to increase the efficacy and the tolerability of preparations based on the use of compounds used to carry out chemical peeling, comprising at least one keratolytic agent and dimethyl isosorbide. The composition may additionally comprise dimethyl sulphone. | 08-07-2014 |
20140288169 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS - The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions. | 09-25-2014 |
20140315996 | USE OF ISOSORBIDE MONOESTERS AS ANTIMICROBIAL ACTIVE SUBSTANCES - The use of one or more compounds of the formula (I) | 10-23-2014 |
20140323564 | COMPOSITION CONTAINING ISOSORBIDE MONOESTER AND ISOSORBIDE DIESTER - What are described are compositions comprising | 10-30-2014 |
20150011622 | Dosage Form Containing Extract From Bark of Liriodendron Tulipifera as Active Ingredient - The present invention relates to an improved dosage form containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of | 01-08-2015 |
20150011623 | Pharmaceutical Composition Containing as Active Ingredient Extract From Bark of Liriodendron Tulipifera - The present invention relates to a pharmaceutical composition containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of | 01-08-2015 |
20150011624 | Method for extracting treatment ingredients for gastrointestinal diseases from bark of liriodendron tulipifera - The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of | 01-08-2015 |
20150031760 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISORDERS COMPRISING SULFURETIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition for preventing or treating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof, and a method of using the composition to prevent or treat nervous system disorders. Moreover, the present invention relates to a functional food composition for alleviating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof. The pharmaceutical composition and the functional food composition can be effectively used to prevent or treat degenerative brain disorders caused by a variety of cerebral nervous system abnormalities in persons, as well as depressive disorder and anxiety. | 01-29-2015 |
20150038575 | MELANOGENESIS-INHIBITORY CONSTITUENTS OF Ligusticum sinense - Melanogenesis-inhibitory constituents of | 02-05-2015 |
20150038576 | COMPOSITIONS AND THEIR USE FOR SMOKING CESSATION AND OTHER TREATMENTS - A composition includes a liquid. The liquid aerosolizes for delivery to a user by an airway. The liquid includes an agent that activates a TRPV3 channel. The agent includes a terpenoid compound. | 02-05-2015 |
20150111962 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS - Macrocycle containing carbamate compounds that inhibit HIV proteolytic enzymes and processes for preparing them are described. Compositions and methods for treating a patient infected with HIV are described. | 04-23-2015 |
20150126599 | PROCESS FOR PRODUCING ISOHEXIDES - A process is described for producing an isohexide wherein an hexitol or a combination of hexitols is continuously dehydrated in the presence of an acid catalyst under vacuum using a thin film evaporator. | 05-07-2015 |
20150148412 | POLYMORPHS OF DARUNAVIR - The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection. | 05-28-2015 |
20150306233 | STABLE PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising:
| 10-29-2015 |
20150307510 | IMPROVED METHOD OF MAKING INTERNAL DEHYDRATION PRODUCTS OF SUGAR ALCOHOLS - A process is provided for making isohexides such as isosorbide with reduced color and/or improved color stability on storage, wherein ionic species in the crude dehydration product mixture are chromatographically substantially separated from the remainder of the crude product mixture, then the remainder is refined to yield a finished product for further use or sale. | 10-29-2015 |
20150320718 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed. | 11-12-2015 |
20150352213 | METHOD FOR TREATING PANCREATIC CANCER - A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide. | 12-10-2015 |
20160000080 | COMPOSITIONS CONTAINING ISOSORBIDE MONOESTER AND ALIPHATIC VICINAL DIOLS - What are described are compositions comprising
| 01-07-2016 |
20160000751 | METHOD FOR TREATING AND/OR DELAYING THE DEGENERATION OF PURKINJE CELLS - A method for treating and/or delaying the degeneration of Purkinje cells in a subject is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a medicament, wherein the medicament comprises a phthalide selected from the group consisting of n-butylidenephthalide (BP), a metabolic precursor of BP, a pharmaceutically acceptable salt of a metabolic precursor of BP, a pharmaceutically acceptable ester of a metabolic precursor of BP, and combinations thereof. | 01-07-2016 |
20160031898 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C - Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediated by K-Ras, H-Ras or N-ras G12C. | 02-04-2016 |
20160081978 | PHARMACEUTICAL COMPOSITION CONTAINING LIRIODENDRON TULIPIFERA L. EXTRACT FOR TREATING CHRONIC MYELOGENOUS LEUKEMIA - The present invention relates to a pharmaceutical composition containing, as an active ingredient, a | 03-24-2016 |
20160081979 | METHOD FOR SEPARATING THERAPEUTIC AGENT FOR CHRONIC MYELOGENOUS LEUKEMIA FROM BARK OF LIRIODENDRON TULIPIFERA L. - The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of T315I, which is known as a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of | 03-24-2016 |
20160136126 | Pharmaceutical compositions of Anisomelic acid and the use thereof - A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof. A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided. | 05-19-2016 |
20190144461 | PROCESS FOR PREPARATION OF DARUNAVIR | 05-16-2019 |